3 results
To evaluate the perioperative hemostatic efficacy of BAX 802 in male subjects with CHA with inhibitors to human factor VIII (hFVIII) undergoing major or minor elective surgical, dental, or other invasive procedures as determined by the Global…
The study is designed to substantiate the efficacy of CCM in the heart failure population with ejection fraction ranging between 25 and 45%. The study is designed in an adaptive manner to ensure proper statistical significance and power of the…
The primary objective of the study is survival on a Carmat device at 180 days post-implant* or survival to cardiac transplantation if occurring before 180 days post-implant**. * The beginning of the implant procedure is defined as the start of the…